The Miami Entrepreneur

Trevi’s stock gains 38% after announcing positive data for skin-disease drug

Shares of Trevi Therapeutics Inc. jumped 38.1% in premarket trading on Wednesday after the company said its experimental treatment for prurigo nodularis, a type of inflammatory skin disease, met the primary endpoint in a Phase 2b/3 clinical trial. If approved, the oral treatment would be the first therapy to treat prurigo nodularis, Trevi said. The company’s stock has soared 158.2% this year, while the broader S&P 500 is down 19.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Previous post PayChex tops profit and revenue expectations, provides upbeat outlook
Next post Crypto: Bitcoin could experience a ‘final washout’ decline before reaching a bottom of $13,000, this technical analyst says